Mylan Inc (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

34.05USD
1 Aug 2013
Price Change (% chg)

$0.49 (+1.46%)
Prev Close
$33.56
Open
$33.73
Day's High
$34.62
Day's Low
$33.73
Volume
157,779
Avg. Vol
1,206,224
52-wk High
$34.62
52-wk Low
$22.51

MYL.OQ

Chart for MYL.OQ

About

Mylan Inc. (Mylan) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan has two segments:Generics and Specialty. Its generic pharmaceutical business is conducted primarily in the United States and Canada... (more)

Overall

Beta: 0.78
Market Cap (Mil.): $12,789.37
Shares Outstanding (Mil.): 381.09
Dividend: --
Yield (%): --

Financials

  MYL.OQ Industry Sector
P/E (TTM): 22.46 37.93 37.76
EPS (TTM): 1.49 -- --
ROI: 6.40 19.48 18.76
ROE: 18.54 20.17 19.59
Search Stocks

Mylan earnings rise, but dollar drags on revenue

- Mylan Inc's quarterly earnings rose 28 percent, but the generic drugmaker said the weakness of the Indian and Japanese currencies against the dollar would put 2013 revenue at the low end of its forecast range of $7 billion to $7.4 billion.

8:21am EDT

UPDATE 1-Mylan earnings rise, but dollar drags on revenue

Aug 1 - Mylan Inc's quarterly earnings rose 28 percent, but the generic drugmaker said the weakness of the Indian and Japanese currencies against the dollar would put 2013 revenue at the low end of its forecast range of $7 billion to $7.4 billion.

8:20am EDT

Mylan second quarter earnings rise, but foreign exchange drags

Aug 1 - Generic drugmaker Mylan Inc said on Thursday that its second-quarter earnings rose, but forecast 2013 revenue would be at the low end of an expected $7 billion to $7.4 billion range because of the weakening of India's and Japan's currencies against the dollar.

8:04am EDT

Mylan says court dismisses some of Teva's patent claims on MS drug

- A federal court in New York ruled that Mylan Inc's generic application for a multiple sclerosis drug has not infringed some of Teva Pharmaceutical Industries' patents, Mylan said.

16 Jul 2013

Mylan says court dismisses some of Teva's patent claims on MS drug

July 16 - A federal court in New York ruled that Mylan Inc's generic application for a multiple sclerosis drug has not infringed some of Teva Pharmaceutical Industries' patents, Mylan said.

16 Jul 2013

DEALTALK: Game may not be over for Royalty' Pharma's bid for Elan

NEW YORK, June 27 - The game may not yet be over for U.S investment firm Royalty Pharma in its months-long pursuit of Elan Corp.

27 Jun 2013

Warner Chilcott buy may be Actavis' best takeover defense

NEW YORK - Generic drugmaker Actavis , the subject of intense takeover speculation, may have found its best defense: a potential purchase of Warner Chilcott Plc , a specialty pharmaceutical company that has been for sale on and off for years.

17 May 2013

Market Chatter-Corporate finance press digest

May 15 - The following corporate finance-related stories were reported by media on Wednesday:

15 May 2013

Actavis rejected $15 billion offer from Mylan: source

NEW YORK - Actavis Inc received and rejected a takeover offer from Mylan Inc last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation told Reuters on Tuesday.

14 May 2013

Actavis rejected $15 billion offer from Mylan - source

NEW YORK, May 14 - Actavis Inc received and rejected a takeover offer from Mylan Inc last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation told Reuters on Tuesday.

14 May 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$58.00
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$495.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks